search
Back to results

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

Primary Purpose

Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Nanatinostat in combination with valganciclovir
Sponsored by
Viracta Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Epstein-Barr Virus Associated Lymphoproliferative Disorder focused on measuring EBV positive post-transplant lymphoproliferative disorder (PTLD), EBV lymphoma, HIV-associated lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus (EBV), EBV positive T cell lymphoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • EBV+ relapsed/refractory lymphoma following 2 or more prior systemic therapies
  • EBV+ DLBCL, NOS: Must have received at least one course of an anti-CD20 immunotherapy, and at least one course of anthracycline-based chemotherapy
  • PTLD: Must have received immunotherapy with an anti-CD20 agent.
  • Hodgkin lymphoma: Must have received at least one course of anthracycline-based chemotherapy. Patients with classical Hodgkin lymphoma should have failed or be ineligible for an anti-PD-1 agent and CD30-directed therapy.
  • For ENKTL and PTCL patients only: Relapsed/refractory disease following 1 or more prior systemic therapies. ENKTL patients must have failed an asparaginase-containing regimen.
  • No available therapies in the opinion of the Investigator
  • Not eligible for high-dose chemotherapy with allogeneic/autologous stem cell transplantation or CAR-T therapy
  • Measurable disease per Lugano 2007
  • ECOG performance status 0, 1, 2
  • Adequate bone marrow function

Key Exclusion Criteria:

  • Presence or history of CNS involvement by lymphoma
  • Systemic anticancer therapy or CAR-T within 21 days
  • Antibody (anticancer) agents within 28 days
  • Less than 60 days from prior autologous hematopoietic stem cell or solid organ transplant
  • Less than 90 days from prior allogeneic transplant.
  • Daily corticosteroids (≥20 mg of prednisone or equivalent) within week prior to Cycle 1 Day 1
  • Inability to take oral medication, malabsorption syndrome or any other gastrointestinal condition (nausea, diarrhea, vomiting) that may impact the absorption of nanatinostat and valganciclovir.
  • Active infection requiring systemic therapy (excluding viral upper respiratory tract infections).

Sites / Locations

  • The University of Alabama at Birmingham Comprehensive Cancer CenterRecruiting
  • University of Arizona Cancer CenterRecruiting
  • David Geffen School of Medicine - UCLARecruiting
  • University of California IrvineRecruiting
  • Scripps MD Anderson Cancer CenterRecruiting
  • UCSF Hematology and Blood and Marrow TransplantRecruiting
  • The Oncology Institute of Hope and InnovationRecruiting
  • University of Colorado Cancer CenterRecruiting
  • Mid Florida Hematology and Oncology CenterRecruiting
  • Winship Cancer Institute of Emory University
  • Norton Cancer InstituteRecruiting
  • University of Maryland Medical CenterRecruiting
  • St. Vincent Healthcare Cancer CenterRecruiting
  • Dartmouth Hitchcock Medical CenterRecruiting
  • John Theurer Cancer Center: Hackensack UniveristyRecruiting
  • Roswell Park Comprehensive Cancer CenterRecruiting
  • Icahn School of Medicine at Mount SinaiRecruiting
  • Memorial Sloan Kettering Cancer Center - New YorkRecruiting
  • Duke Cancer Institute
  • Ohio State University: Wexner Medical Center
  • Sidney Kimmel Cancer Center - Jefferson HealthRecruiting
  • Medical University of South CarolinaRecruiting
  • Harold C. Simmons Comprehensive Cancer CenterRecruiting
  • The University of Texas MD Anderson Cancer CenterRecruiting
  • Seattle Cancer Care AllianceRecruiting
  • Box Hill HospitalRecruiting
  • The Alfred HospitalRecruiting
  • CEPEVILLE - Instituto Joinvilense de Hematologia e Oncologia
  • Ruschel Medicina e Pesquisa Clinica
  • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
  • CIPE Centro Internacional de Pesquisa - AC Camargo Cancer Center
  • HCFMUSP - Hospital das Clínicas da Faculdade de Medicina Universidade de São Paulo
  • Cross Cancer InstituteRecruiting
  • BC Cancer AgencyRecruiting
  • Princess Margaret Cancer CentreRecruiting
  • Hôpital Maisonneuve-RosemontRecruiting
  • Institut BergoniéRecruiting
  • Hôpital Universitaire Pitié SalpêtrièreRecruiting
  • Centre Hospitalier Universitaire LimogesRecruiting
  • Hôpital Haut-LévêqueRecruiting
  • Centre Hospitalier Départemental VendéeRecruiting
  • Hôpital Saint-EloiRecruiting
  • Centre Hospitalier Lyon-SudRecruiting
  • Paoli-Calmettes InstituteRecruiting
  • Henri Mondor University HospitalRecruiting
  • Universitätsklinikum WürzburgRecruiting
  • Klinikum OldenburgRecruiting
  • Universitätsklinikum EssenRecruiting
  • Klinikum ChemnitzRecruiting
  • Evangelisches Diakonie Hospital (DIAKO)
  • Martin-Luther-UniversitätRecruiting
  • Universitätsklinikum Leipzig
  • Klinik für Hämatologie und Onkologie, UKSH Campus Lübeck
  • Universitatsmedizin MannheimRecruiting
  • Queen Mary Hospital/University of Hong KongRecruiting
  • Hadassah Medical Center, Ein Kerem Hospital
  • Tel Aviv Sourasky Medical Center
  • Ospedale Casa Sollievo della SofferenzaRecruiting
  • Istituto Clinico HumanitasRecruiting
  • Centro di Riferimento OncologicoRecruiting
  • Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant Orsola-MalpighiRecruiting
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaRecruiting
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano NiguardaRecruiting
  • Istituto Europeo di OncologiaRecruiting
  • Fondazione IRCCS Policlinico San MatteoRecruiting
  • Arcispedale Santa Maria NuovaRecruiting
  • Fondazione Policlinico Universitario Agostino GemelliRecruiting
  • Keimyung University Dongsan HospitalRecruiting
  • Inje University Busan Paik HospitalRecruiting
  • Kyungpook National University HospitalRecruiting
  • Gachon University Gil Medical CenterRecruiting
  • Samsung Medical Center
  • The Catholic University of Korea, Seoul St. Mary's HospitalRecruiting
  • University of Malaya
  • Sarawak General Hospital / Hospital Umum Sarawak
  • National Cancer Centre SingaporeRecruiting
  • Oncocare Cancer CenterRecruiting
  • Singapore General HospitalRecruiting
  • Hospitalet de LlobregatRecruiting
  • Hospital Universitario 12 de OctubreRecruiting
  • Jimenez Diaz Foundation University HospitalRecruiting
  • Taipei Veterans General HospitalRecruiting
  • Kaohsiung Chang Gung Memorial HospitalRecruiting
  • Kaohsiung Medical University Chung-Ho Memorial HospitalRecruiting
  • China Medical University HospitalRecruiting
  • National Cheng Kung University HospitalRecruiting
  • National Taiwan University HospitalRecruiting
  • Mackay Memorial Hospital - Taipei
  • Chang Gung Memorial Hospital - Linkou BranchRecruiting
  • The Clatterbridge Cancer Centre NHS Foundation TrustRecruiting
  • Kings College Hospital
  • The Royal Marsden NHS Foundation Trust
  • University College London Hospitals NHS Foundation TrustRecruiting
  • The Christie NHS Foundation TrustRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Nanatinostat with Valganciclovir

Arm Description

Patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week with valganciclovir 900 mg orally once daily. Up to 10 PTCL patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week.

Outcomes

Primary Outcome Measures

Objective response rate (ORR)
Assessed by an Independent Review Committee (IRC) per the 2007 International Working Group Response Criteria (IWGRC)

Secondary Outcome Measures

Duration of response (DOR)
Time to next anti-lymphoma treatment (TTNLT)
Progression-free survival (PFS)
Time to progression (TTP)
Overall survival
Incidence and severity of treatment-emergent adverse events
Pharmacokinetic parameter - time to maximum plasma concentration [tmax],
Pharmacokinetic parameter - maximum plasma concentration [Cmax]
Pharmacokinetic parameter - area under the plasma concentration-time curve [AUC]

Full Information

First Posted
August 2, 2021
Last Updated
September 29, 2023
Sponsor
Viracta Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05011058
Brief Title
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Acronym
NAVAL-1
Official Title
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 28, 2021 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
December 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Viracta Therapeutics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
Detailed Description
Patients with EBV-associated lymphomas have inferior outcomes with standard-of-care therapies compared to those with EBV-negative disease. Nanatinostat is a selective class I HDAC inhibitor which induces EBV lytic phase protein generation, activating (val)ganciclovir to its cytotoxic form. This open-label, multicenter, multinational, single-arm, Phase 2 basket study employs a Simon's 2-stage design to allow termination of enrollment into cohorts where treatment appears futile, and will include the following cohorts of patients with EBV+ relapsed/refractory lymphomas: EBV+ diffuse large B-cell lymphoma (DLBCL, NOS) Extranodal NK/T-cell lymphoma (ENKTL) Peripheral T-cell lymphoma (PTCL), including PTCL-NOS and AITL Hodgkin lymphoma (HL) Post-transplant lymphoproliferative disorder (PTLD) HIV-associated lymphomas (Plasmablastic, Burkitt, Hodgkin, DLBCL) EBV+ lymphoproliferative disorders other than the above

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma, Extranodal NK/T-cell Lymphoma, EBV-Positive DLBCL, Nos, EBV Associated Lymphoma, EBV-Related Hodgkin Lymphoma, EBV Related PTCL, Nos
Keywords
EBV positive post-transplant lymphoproliferative disorder (PTLD), EBV lymphoma, HIV-associated lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus (EBV), EBV positive T cell lymphoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
This is an open-label, single-arm study utilizing a basket trial design.
Masking
None (Open Label)
Allocation
N/A
Enrollment
140 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Nanatinostat with Valganciclovir
Arm Type
Experimental
Arm Description
Patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week with valganciclovir 900 mg orally once daily. Up to 10 PTCL patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week.
Intervention Type
Drug
Intervention Name(s)
Nanatinostat in combination with valganciclovir
Intervention Description
Drug: Nanatinostat, 20 mg orally once daily, 4 days per week in 28 day cycles Other name: VRx-3996 Drug: Valganciclovir, 900 mg orally once daily in 28 day cycles
Primary Outcome Measure Information:
Title
Objective response rate (ORR)
Description
Assessed by an Independent Review Committee (IRC) per the 2007 International Working Group Response Criteria (IWGRC)
Time Frame
Approximately 3 years
Secondary Outcome Measure Information:
Title
Duration of response (DOR)
Time Frame
Approximately 3 years
Title
Time to next anti-lymphoma treatment (TTNLT)
Time Frame
Approximately 3 years
Title
Progression-free survival (PFS)
Time Frame
Approximately 3 years
Title
Time to progression (TTP)
Time Frame
Approximately 3 years
Title
Overall survival
Time Frame
Approximately 3 years
Title
Incidence and severity of treatment-emergent adverse events
Time Frame
Approximately 28 days following the last dose
Title
Pharmacokinetic parameter - time to maximum plasma concentration [tmax],
Time Frame
Approximately 6 months following the end of Cycle 1 Day 1 (each cycle is 28 days)
Title
Pharmacokinetic parameter - maximum plasma concentration [Cmax]
Time Frame
Approximately 6 months following the end of Cycle 1 Day 1 (each cycle is 28 days)
Title
Pharmacokinetic parameter - area under the plasma concentration-time curve [AUC]
Time Frame
Approximately 6 months following the end of Cycle 1 Day 1 (each cycle is 28 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: EBV+ relapsed/refractory lymphoma following 2 or more prior systemic therapies EBV+ DLBCL, NOS: Must have received at least one course of an anti-CD20 immunotherapy, and at least one course of anthracycline-based chemotherapy PTLD: Must have received immunotherapy with an anti-CD20 agent. Hodgkin lymphoma: Must have received at least one course of anthracycline-based chemotherapy. Patients with classical Hodgkin lymphoma should have failed or be ineligible for an anti-PD-1 agent and CD30-directed therapy. For ENKTL and PTCL patients only: Relapsed/refractory disease following 1 or more prior systemic therapies. ENKTL patients must have failed an asparaginase-containing regimen. No available therapies in the opinion of the Investigator Not eligible for high-dose chemotherapy with allogeneic/autologous stem cell transplantation or CAR-T therapy Measurable disease per Lugano 2007 ECOG performance status 0, 1, 2 Adequate bone marrow function Key Exclusion Criteria: Presence or history of CNS involvement by lymphoma Systemic anticancer therapy or CAR-T within 21 days Antibody (anticancer) agents within 28 days Less than 60 days from prior autologous hematopoietic stem cell or solid organ transplant Less than 90 days from prior allogeneic transplant. Daily corticosteroids (≥20 mg of prednisone or equivalent) within week prior to Cycle 1 Day 1 Inability to take oral medication, malabsorption syndrome or any other gastrointestinal condition (nausea, diarrhea, vomiting) that may impact the absorption of nanatinostat and valganciclovir. Active infection requiring systemic therapy (excluding viral upper respiratory tract infections).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Strait Hicklin
Phone
858-400-8470
Email
ClinicalTrials@Viracta.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Donald (D.K.) Strickland, MD
Organizational Affiliation
Viracta Therapeutics
Official's Role
Study Director
Facility Information:
Facility Name
The University of Alabama at Birmingham Comprehensive Cancer Center
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
University of Arizona Cancer Center
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85719
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
David Geffen School of Medicine - UCLA
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
University of California Irvine
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Scripps MD Anderson Cancer Center
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
UCSF Hematology and Blood and Marrow Transplant
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
The Oncology Institute of Hope and Innovation
City
Torrance
State/Province
California
ZIP/Postal Code
90503
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
University of Colorado Cancer Center
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Mid Florida Hematology and Oncology Center
City
Orange City
State/Province
Florida
ZIP/Postal Code
32763
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Winship Cancer Institute of Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Norton Cancer Institute
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40241
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
University of Maryland Medical Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
St. Vincent Healthcare Cancer Center
City
Billings
State/Province
Montana
ZIP/Postal Code
59102
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Dartmouth Hitchcock Medical Center
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03766
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
John Theurer Cancer Center: Hackensack Univeristy
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Roswell Park Comprehensive Cancer Center
City
Buffalo
State/Province
New York
ZIP/Postal Code
14203
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Memorial Sloan Kettering Cancer Center - New York
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Duke Cancer Institute
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Ohio State University: Wexner Medical Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Sidney Kimmel Cancer Center - Jefferson Health
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Harold C. Simmons Comprehensive Cancer Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75235
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
The University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Seattle Cancer Care Alliance
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Box Hill Hospital
City
Melbourne
State/Province
Victoria
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
The Alfred Hospital
City
Melbourne
State/Province
Victoria
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
CEPEVILLE - Instituto Joinvilense de Hematologia e Oncologia
City
Joinville
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Ruschel Medicina e Pesquisa Clinica
City
Rio De Janeiro
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
City
Santo André
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
CIPE Centro Internacional de Pesquisa - AC Camargo Cancer Center
City
São Paulo
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
HCFMUSP - Hospital das Clínicas da Faculdade de Medicina Universidade de São Paulo
City
São Paulo
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Cross Cancer Institute
City
Edmonton
State/Province
Alberta
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
BC Cancer Agency
City
Vancouver
State/Province
British Columbia
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Princess Margaret Cancer Centre
City
Toronto
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Hôpital Maisonneuve-Rosemont
City
Montréal
State/Province
Quebec
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Institut Bergonié
City
Bordeaux Cedex
State/Province
Aquitaine
Country
France
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Hôpital Universitaire Pitié Salpêtrière
City
Paris
State/Province
Ile-de-France
Country
France
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Centre Hospitalier Universitaire Limoges
City
Limoges cedex
State/Province
Limousin
Country
France
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Hôpital Haut-Lévêque
City
Pessac
State/Province
Nouvelle-Aquitaine
Country
France
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Centre Hospitalier Départemental Vendée
City
La Roche-sur-Yon
State/Province
Pays De La Loire
Country
France
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Hôpital Saint-Eloi
City
Montpellier Cedex 5
State/Province
Provence Alpes Cote d'Azur
Country
France
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Centre Hospitalier Lyon-Sud
City
Pierre-Bénite
State/Province
Rhone-Alps
Country
France
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Paoli-Calmettes Institute
City
Marseille
Country
France
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Henri Mondor University Hospital
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Universitätsklinikum Würzburg
City
Würzburg
State/Province
Bavaria
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Klinikum Oldenburg
City
Oldenburg
State/Province
Niedersachsen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Universitätsklinikum Essen
City
Essen
State/Province
Nordrhein-Westfalen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Klinikum Chemnitz
City
Chemnitz
State/Province
Saxony
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Evangelisches Diakonie Hospital (DIAKO)
City
Bremen
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Martin-Luther-Universität
City
Halle
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Universitätsklinikum Leipzig
City
Leipzig
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Klinik für Hämatologie und Onkologie, UKSH Campus Lübeck
City
Lübeck
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Universitatsmedizin Mannheim
City
Mannheim
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Queen Mary Hospital/University of Hong Kong
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Hadassah Medical Center, Ein Kerem Hospital
City
Jerusalem
Country
Israel
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Tel Aviv Sourasky Medical Center
City
Tel Aviv
Country
Israel
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Ospedale Casa Sollievo della Sofferenza
City
San Giovanni Rotondo
State/Province
Foggia
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Istituto Clinico Humanitas
City
Rozzano
State/Province
Milan
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Centro di Riferimento Oncologico
City
Aviano
State/Province
Pordenone
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant Orsola-Malpighi
City
Bologna
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
City
Brescia
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
City
Milano
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Istituto Europeo di Oncologia
City
Milano
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Fondazione IRCCS Policlinico San Matteo
City
Pavia
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Arcispedale Santa Maria Nuova
City
Reggio Emilia
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Fondazione Policlinico Universitario Agostino Gemelli
City
Roma
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Keimyung University Dongsan Hospital
City
Daegu
State/Province
Gyeongsangbugdo
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Inje University Busan Paik Hospital
City
Busan
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Kyungpook National University Hospital
City
Daegu
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Gachon University Gil Medical Center
City
Incheon
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Samsung Medical Center
City
Seoul
Country
Korea, Republic of
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
The Catholic University of Korea, Seoul St. Mary's Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
University of Malaya
City
Kuala Lumpur
Country
Malaysia
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Sarawak General Hospital / Hospital Umum Sarawak
City
Kuching
Country
Malaysia
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
National Cancer Centre Singapore
City
Singapore
Country
Singapore
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Oncocare Cancer Center
City
Singapore
Country
Singapore
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Singapore General Hospital
City
Singapore
Country
Singapore
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Hospitalet de Llobregat
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
ClinicalTrials@viracta.com
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Jimenez Diaz Foundation University Hospital
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Taipei Veterans General Hospital
City
Taipei City
State/Province
Taipei
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Kaohsiung Chang Gung Memorial Hospital
City
Kaohsiung
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Kaohsiung Medical University Chung-Ho Memorial Hospital
City
Kaohsiung
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
China Medical University Hospital
City
Taichung City
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
National Cheng Kung University Hospital
City
Tainan
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
National Taiwan University Hospital
City
Taipei City
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Mackay Memorial Hospital - Taipei
City
Taipei
Country
Taiwan
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
Chang Gung Memorial Hospital - Linkou Branch
City
Taoyuan City
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
The Clatterbridge Cancer Centre NHS Foundation Trust
City
Liverpool
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
Kings College Hospital
City
London
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
The Royal Marsden NHS Foundation Trust
City
London
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
Email
ClinicalTrials@viracta.com
Facility Name
University College London Hospitals NHS Foundation Trust
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com
Facility Name
The Christie NHS Foundation Trust
City
Manchester
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@Viracta.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

We'll reach out to this number within 24 hrs